What does the EMPA-REG OUTCOME study mean for a general practitioner? Review article
Article Sidebar
Published:
Dec 31, 2020
Keywords:
diabetes, cardiovascular risk, empagliflozin
Main Article Content
Abstract
At work we discuss the conclusions of the three-year EMPA-REG OUTCOME study in which patients with second type diabetes with high cardiovascular risk were treated with addition of empagliflozin.
Article Details
How to Cite
Sapilak , B. J., Mastalerz-Migas, A., & Dzida , G. (2020). What does the EMPA-REG OUTCOME study mean for a general practitioner?. Medycyna Faktow (J EBM), 13(4(49), 395-398. https://doi.org/10.24292/01.MF.0420.2
Issue
Section
Articles
Copyright by Medical Education. All rights reserved.
References
1. Sarwar N, Gao P, Seshasai SR et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborativevmeta-analysis of 102 prospective studies. Lancet. 2010; 375: 2215-22.
2. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008; 358: 2545-59.
3. The ADVANCE Collaborative Group: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008; 358: 2560-72.
4. Duckworth W, Abraira C, Moritz T et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009; 360: 129-39.
5. Inzucchi SE, Zinman B, Wanner C et al. SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials. Diab Vasc Dis Res. 2015; 12: 90-100.
6. Zinman B, Wanner C, Lachin JM et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015; 373(22): 2117-28. http://doi.org/10.1056/NEJMoa1504720.
7. Fitchett D, Zinman B, Wanner C et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME? trial. Eur Heart J. 2016; 37(19): 1526-34.
8. Perreault L. EMPA-REG OUTCOME: the endocrinologist?spoint of view. Am J Med. 2017; 130(6S): S51-S6. http://doi.org/10.1016/j.amjmed.2017.04.005.
9. Bays H. Sodium glucose co-transporter type 2 (SGLT2) inhibitors: targeting the kidney to improve glycemic control in diabetes mellitus. Diabetes Ther. 2013; 4: 195-220.
10. Tahrani AA, Barnett AH, Bailey CJ. SGLT inhibitors in management of diabetes. Lancet Diabetes Endocrinol. 2013; 2: 140-51.
11. Hasan FM, Alsahli M, Gerich J.E. SGLT2 inhibitors in the treatment of type 2 diabetes. Diab Res Clin Pract. 2014; 104: 297-322.
2. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008; 358: 2545-59.
3. The ADVANCE Collaborative Group: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008; 358: 2560-72.
4. Duckworth W, Abraira C, Moritz T et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009; 360: 129-39.
5. Inzucchi SE, Zinman B, Wanner C et al. SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials. Diab Vasc Dis Res. 2015; 12: 90-100.
6. Zinman B, Wanner C, Lachin JM et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015; 373(22): 2117-28. http://doi.org/10.1056/NEJMoa1504720.
7. Fitchett D, Zinman B, Wanner C et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME? trial. Eur Heart J. 2016; 37(19): 1526-34.
8. Perreault L. EMPA-REG OUTCOME: the endocrinologist?spoint of view. Am J Med. 2017; 130(6S): S51-S6. http://doi.org/10.1016/j.amjmed.2017.04.005.
9. Bays H. Sodium glucose co-transporter type 2 (SGLT2) inhibitors: targeting the kidney to improve glycemic control in diabetes mellitus. Diabetes Ther. 2013; 4: 195-220.
10. Tahrani AA, Barnett AH, Bailey CJ. SGLT inhibitors in management of diabetes. Lancet Diabetes Endocrinol. 2013; 2: 140-51.
11. Hasan FM, Alsahli M, Gerich J.E. SGLT2 inhibitors in the treatment of type 2 diabetes. Diab Res Clin Pract. 2014; 104: 297-322.